Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Compiled: PRESS AND THIRD PARTY COVERAGE: 09/29/19

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
XenaLives Member Profile
Member Level 
Followed By 316
Posts 40,630
Boards Moderated 29
Alias Born 09/20/01
160x600 placeholder
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
XenaLives Member Level  Sunday, 09/29/19 11:42:51 AM
Re: None
Post # of 232562 
Compiled: PRESS AND THIRD PARTY COVERAGE: 09/29/19
______________________________________________________________________________________


"Additionally, after seven weeks of treatment, blood levels of the neurotransmitter glutamate decreased significantly, while levels of another neurotransmitter, GABA, or gamma-aminobutyric acid, increased significantly. A neurotransmitter is a chemical molecule that allows nerve cells to communicate. In Rett syndrome, there tend to be abnormally high glutamate levels and abnormally low GABA levels. As such, these results suggest a “balancing” of neurotransmitter levels."
https://rettsyndromenews.com/2019/09/19/preliminary-trial-data-anavex-2-73-rett-syndrome-suggest-safety-efficacy/

Mayo Clinic researcher states that the P2a improved cognition and function:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149549864

S&P Global Market Intelligence, quoting Dr. Missling:
Failures in Alzheimer's research spur new approaches to drug development
Discussion follows:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149043113

Experimental pill shows promising results for Parkinson's
https://pressfrom.info/au/lifestyle/health/-121247-experimental-pill-shows-promising-results-for-parkinson-s.html

NEWS!!! March 4, 2019 Third party paper on cellular recycling.
https://www.anavex.com/anavex-life-sciences-reports-publication-of-new-data-that-show-anavex2-73-induces-cellular-recycling-process-linked-to-the-prevention-and-treatment-of-age-associated-diseases/

access to above paper
https://www.mdpi.com/2073-4409/8/3/211/htm

What is proteostasis?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147258047

This MOA applies to the aging process in general:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147257995

There is a complete section on autophagy in the MOA and Medical compiled post

Anavex 2-73 and a Nobel Prize winner (from georgejjl)


Richard Engel on his son with Rett Syndrome:
https://www.today.com/parents/rett-syndrome-richard-engel-son-henry-s-milestone-life-special-t150348
A January 2018 article by Engel talks about how his son's genes are being used for research
https://www.today.com/parents/rett-syndrome-richard-engel-shares-his-son-s-rare-condition-t121886

Videos of Australian Patients from the P2a trial





Pauline Stevens the Pianist.
https://www.geelongadvertiser.com.au/news/steve-macfarlane-explains-the-alzheimers-worldfirst-drug-trial-at-caulfield-hospital/video/03fe27ae89bdce4912cabf865a99ed80

Extended P2a participant regains driver's license:

https://www.australianageingagenda.com.au/2018/07/13/next-stage-of-national-drug-trial-underway/

Thanks to polarbear for this link.. all I can say is "It's about time"...
https://alzheimersnewstoday.com/2018/10/31/anavex-2-73-slows-cognitive-decline-alzheimers-extension-study/

CA governor's task force

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=146900633

Press coverage of AVXL at 2018 CTAD:
http://cnafinance.com/anavex-life-sciences-avxl-stock-gaining-on-clinical-data/20696
http://www.bioworld.com/content/tiny-anavex-thinks-big-three-year-ad-data-ctad

Recent press coverage of the 2-73 Alzheimer's trial in Australia per TTTav66:

https://www.9news.com.au/2018/10/19/18/29/dementia-pill-clinical-trial-anavex-2-73

Australian press covering the 2-73 trial:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772297
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143773822

Apologies and thanks to the poster who first posted this article, having trouble keeping up with the good news:
https://www.yourlifechoices.com.au/health/news/alzheimers-trial-delivers-results

When the hugs and kisses stopped...
https://www.abc.net.au/news/2018-11-14/dementia-onset-when-the-hugs-stopped/10433574

UK press covering the 2-73 trial (repeat of AU coverage):
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143772909



Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist